Comparative Pharmacology
Head-to-head clinical analysis: AEROSEB HC versus AMCINONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROSEB HC versus AMCINONIDE.
AEROSEB-HC vs AMCINONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROSEB-HC (hydrocortisone/iodoquinol) exerts anti-inflammatory, antipruritic, and antifungal actions. Hydrocortisone suppresses inflammatory mediators via glucocorticoid receptor binding, while iodoquinol provides antimicrobial activity against dermatophytes and bacteria.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.
AEROSEB-HC (hydrocortisone/iodoquinol) topical cream: Apply a thin film to affected area twice daily for up to 7 days. Not for ophthalmic or oral use.
Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.
None Documented
None Documented
Clinical Note
moderateAmcinonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Gatifloxacin."
Clinical Note
moderateAmcinonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Rosoxacin."
Clinical Note
moderateAmcinonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Levofloxacin."
Clinical Note
moderateAmcinonide + Trovafloxacin
1.5-2 hours (terminal) after intravenous administration; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 2–4 hours, but following topical application, systemic half-life may be prolonged due to continuous absorption from the skin.
Renal (primarily as metabolites; <5% unchanged); fecal (biliary excretion of metabolites).
Primarily renal; <5% fecal. About 40% of a dose is excreted in urine as unchanged drug and glucuronide conjugates.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Trovafloxacin."